Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Podcasts|November 18, 2026 (Updated: November 17, 2026)

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T

Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today: a regulatory first for biosimilars, a bispecific built for durability in the eye, and a move to make CAR-T therapy same-day.

First, the European Commission has authorized Biocon’s Pebrilzo, a biosimilar to Perjeta, or pertuzumab, for HER2-positive breast cancer. It is the first breast cancer biosimilar approved under EMA’s tailored clinical approach. That framework describes cases where similar efficacy and safety can be inferred from analytical and pharmacokinetic similarity, without a comparative efficacy trial. FDA approved the product two days earlier, but a settlement with Genentech means it can’t launch in the US before the third quarter of 2028. www.biopharminternational.com

Next, Visara has dosed the first patient in ASCEND, a phase 2b trial of VIS-101 in wet age-related macular degeneration. VIS-101 is a tetravalent bispecific inhibitor of VEGF-A and angiopoietin-2. About 244 patients will receive one of two doses or aflibercept, and the trial tests treatment intervals of up to seven months after loading. Visara plans a global phase 3 program as early as 2027. www.biopharminternational.com

And finally, Verismo Therapeutics has licensed Stanford’s PACK-IT technology. PACK-IT uses engineered, T cell-targeted lentiviral particles to deliver CAR genes to T cells. Verismo will pair it with its KIR-CAR platform. The goal is to shorten the multi-week ex vivo CAR-T process to a same-day dosing step. The PACK-IT evidence is preclinical so far. www.biopharminternational.com

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • Biosimilar efficiency: Pebrilzo’s approval is an early test of whether developers can skip comparative efficacy trials for monoclonal antibody biosimilars.
  • Durability race: ASCEND will test whether VIS-101 can stretch the time between wet AMD injections beyond what current therapies allow.
  • In vivo cell therapy: Verismo is joining the push to make CAR-T off-the-shelf and same-day, though clinical proof is still ahead.

Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.